Real-world data for a CDK4/6 inhibitor, palbociclib, as 1st- or 2nd-line therapy in HR+/HER2- metastatic breast cancer: a multicenter prospective cohort study. - Ishikawa T; Uemura Y; Seki H; Kitada M; Saito T; Yamada K; Takao S; Takabatake D; Yokota T; Kitahara M; Kikawa Y; Yamada A; et al. (Breast cancer research : BCR, 2026)